Applicant, as named in the Orange Book

Upjohn

Next listed expiry: Lyrica Cr on 2 May 2027. 1 products with live protection, 11 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Lyrica Cr · 3 strengths pregabalin	pregabalin	209501	2 May 2027	patent

Recent events

25 Oct 2026Lyrica · Generic approved 24 Feb 2026
25 Oct 2026Xalatan · Generic approved 17 Dec 2025
25 Oct 2026Lyrica · Generic approved 30 Apr 2026
25 Oct 2026Lipitor · Generic approved 13 Nov 2025
25 Oct 2026Xanax · Generic approved 13 Jul 2026
24 Oct 2026Lyrica Cr · Enters 12-month window basis: patent2 May 2027
24 Oct 2026Lyrica Cr · Enters 12-month window basis: patent2 May 2027
24 Oct 2026Lyrica Cr · Enters 12-month window basis: patent2 May 2027

Products without listed protection (11)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Celebrex · 4 strengths celecoxib	celecoxib	020998	open now	no listed protection
Detrol · 2 strengths tolterodine tartrate	tolterodine tartrate	020771	open now	no listed protection
Effexor Xr · 3 strengths venlafaxine hydrochloride	venlafaxine hydrochloride	020699	open now	no listed protection
Inspra · 2 strengths eplerenone	eplerenone	021437	open now	no listed protection
Lipitor · 4 strengths atorvastatin calcium	atorvastatin calcium	020702	open now	no listed protection
Lyrica pregabalin	pregabalin	022488	open now	no listed protection
Lyrica · 8 strengths pregabalin	pregabalin	021446	open now	no listed protection
Relpax · 2 strengths eletriptan hydrobromide	eletriptan hydrobromide	021016	open now	no listed protection
Xalatan latanoprost	latanoprost	020597	open now	no listed protection
Xanax · 4 strengths alprazolam	alprazolam	018276	open now	no listed protection
Xanax Xr · 4 strengths alprazolam	alprazolam	021434	open now	no listed protection